PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2012; 01(02): 59-62
DOI: 10.4103/2278-330X.103711
Mini Symposium on Changing Landscape: Original Article

A cytohistological study of p53 overexpression in ovarian neoplasms

Monisha Choudhury
Department of Pathology, Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital, New Delhi, India
,
Seema Goyal
Department of Pathology, Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital, New Delhi, India
,
Mukta Pujani
Department of Pathology, Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital, New Delhi, India
,
Meenu Pujani
Department of Pathology, Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital, New Delhi, India
› Institutsangaben Source of Support: Nil.
› Weitere Informationen
  als PDF herunterladen Lizenzen und Reprints

Abstract

Background: The present study was undertaken to evaluate the diagnostic accuracy of imprint cytology in ovarian neoplasms, investigate the biological significance of p53 expression in malignant ovarian tumors and correlate it with histological type, grade and stage of tumor. Material and Methods: A total of 50 cases including 25 prospective and 25 retrospective cases were studied. Imprint cytology was performed on 25 ovarian tumors and compared with histopathological diagnosis. p53 immunohistochemistry was performed on all 50 cases. Results: On immunohistochemistry, all the benign tumors were negative for p53 while 42% of primary ovarian malignant tumors were positive. p53 expression was found to have a diagnostic value in differentiating benign from malignant tumors. p53 overexpression did not show any significant correlation with prognostic factors as stage of disease, grade of differentiation and type of tumor. Conclusion: The present study confirms the importance of p53 tumor suppressor gene expression as documented by immunohistochemistry in the differentiation of malignant and benign ovarian tumors.

Key words

Ovary - p53 - tumors


Publikationsverlauf

Artikel online veröffentlicht:
30. Dezember 2020

© 2012. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Souka S, Kamel M, Rocca M, El-Assi M, Hebeishy N, Sheir SH. The combined use of cytological and frozen section in the intraoperative diagnosis of ovarian tumors. Int J GynecolObstet 1990;31:43-6.
  • 2 Rosai J. Special techniques in surgical pathology. In: Rosai J, editor. Rosai and Ackerman′s Surgical Pathology. 9 th ed. St. Louis: Mosby; 2004. p. 37-92.
  • 3 Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8.
  • 4 Nagai Y, Tanaka N, Horiuchi F, Ohki S, Seki K, Sekiya S. Diagnostic accuracy of intraoperative imprint cytology in ovarian epithelial tumors. Int J GynecolObstet 2001;72:159-64.
  • 5 Inoue M, Fujita M, Enomoto T, Morimoto H, Monden T, Shimano T, et al. Immunohistochemical analysis of p53 in gynecologic tumors. Am J ClinPathol 1994;102:665-70.
  • 6 Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J ClinOncol 1994;12:64-9.
  • 7 Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
  • 8 Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. HumPathol 1993;24:1175-9.
  • 9 Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR, et al. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 1997;80:892-8.
  • 10 Ozalp S, Yalcin OT, Minsin TH. Expression of p53 in epithelial ovarian cancer. Int J GynecolObstet 2000;71:277-8.
  • 11 Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RCJr, Berchuck A. Mutation and overexpression of p53 in early stage epithelial ovarian cancer. ObstetGynecol 1993;81:643-50.
  • 12 Min KW, Park MH. The expression of c-erbB-2, EGFR, p53 and Ki-67 in ovarian borderline tumors and carcinomas of the ovary. Korean J Pathol 2007;41:296-306.
  • 13 Psyrri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp RL, et al. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Ann Oncol 2010;18:709-15.
  • 14 Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, et al. p53 Autoantibodies as Potential Detection and Prognostic Biomarkers in Serous Ovarian Cancer. Cancer EpidemiolBiomarkers Prev 2010;19:859-68.